SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPS3)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。小皮质下卒中二级预防（SPS3）项目的总体目标是确定脑小动脉疾病及其两种最常见的临床表现的有效治疗方法：小皮质下卒中（S3，也称为腔隙性卒中）和认知能力下降（血管性痴呆）。S3患者的最佳抗血小板治疗和降压管理以减少卒中复发和认知能力下降尚未确定，可能会产生重要的健康益处。主要目的是确定阿司匹林加氯吡格雷联合抗血小板治疗在减少卒中复发、认知能力下降和主要血管事件方面是否优于阿司匹林。此外，确定“强化”降压至特定目标范围是否优于“常规”高血压管理，以减少卒中复发、认知能力下降和主要血管事件。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall aim of the Secondary Prevention of Small Subcortical Strokes (SPS3) project is to define efficacious therapies for cerebral small artery disease and its two most common clinical manifestations: small subcortical strokes (S3, also called lacunar strokes) and cognitive decline (vascular dementia). Optimal antiplatelet therapy and antihypertensive management of S3 patients to reduce stroke recurrence and cognitive decline has not been defined and is likely to yield important health benefits. Primary aims are to determine whether combination antiplatelet therapy consisting of aspirin plus clopidogrel is superior to aspirin for reducing recurrent stroke, cognitive decline and major vascular events. Also, to determine whether "intensive" blood pressure lowering to a specific target range is superior to "usual" hypertension management for reducing recurrent stroke, cognitive decline and major vascular events.